Bright Minds Biosciences (NASDAQ:DRUG - Get Free Report) is expected to post its quarterly earnings results before the market opens on Wednesday, May 21st. Analysts expect Bright Minds Biosciences to post earnings of ($0.38) per share for the quarter.
Bright Minds Biosciences (NASDAQ:DRUG - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.23) by $0.24. On average, analysts expect Bright Minds Biosciences to post $-1 EPS for the current fiscal year and $-4 EPS for the next fiscal year.
Bright Minds Biosciences Stock Down 0.0%
NASDAQ DRUG opened at $32.61 on Wednesday. The company has a fifty day moving average of $32.92 and a two-hundred day moving average of $37.07. The firm has a market capitalization of $229.70 million, a price-to-earnings ratio of -191.81 and a beta of -5.32. Bright Minds Biosciences has a 52 week low of $0.93 and a 52 week high of $79.02.
Wall Street Analyst Weigh In
Several analysts have recently weighed in on the company. Chardan Capital assumed coverage on Bright Minds Biosciences in a research report on Wednesday, May 7th. They set a "buy" rating and a $80.00 target price for the company. Piper Sandler assumed coverage on Bright Minds Biosciences in a research report on Thursday, January 23rd. They set an "overweight" rating and a $93.00 target price for the company. TD Cowen assumed coverage on Bright Minds Biosciences in a research report on Tuesday. They set a "buy" rating for the company. Finally, HC Wainwright reiterated a "buy" rating and set a $85.00 target price on shares of Bright Minds Biosciences in a research report on Wednesday, February 19th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $83.25.
Read Our Latest Stock Analysis on Bright Minds Biosciences
About Bright Minds Biosciences
(
Get Free Report)
Bright Minds Biosciences Inc, a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Bright Minds Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bright Minds Biosciences wasn't on the list.
While Bright Minds Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
